{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Control+Subjects&page=40",
    "query": {
      "condition": "Healthy Control Subjects",
      "page": 40
    },
    "page_size": 10
  },
  "pagination": {
    "page": 40,
    "page_size": 10,
    "total_count": 1099,
    "total_pages": 110,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Control+Subjects&page=41&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Control+Subjects&page=39&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-13T02:47:05.293Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05099510",
      "title": "Safety and Pharmacokinetics (PK) Study of Natrunix in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics"
      ],
      "interventions": [
        {
          "name": "Natrunix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "XBiotech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2022-01-19",
      "completion_date": "2022-08-08",
      "has_results": true,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-11-13T02:47:05.293Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05099510"
    },
    {
      "nct_id": "NCT05386823",
      "title": "Evaluate the Safety, Tolerability and PK of HF1K16 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "HF1K16",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HighField Biopharmaceuticals Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 16,
      "start_date": "2021-03-20",
      "completion_date": "2021-08-04",
      "has_results": true,
      "last_update_posted_date": "2024-05-23",
      "last_synced_at": "2026-11-13T02:47:05.293Z",
      "location_count": 1,
      "location_summary": "Secaucus, New Jersey",
      "locations": [
        {
          "city": "Secaucus",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05386823"
    },
    {
      "nct_id": "NCT01037543",
      "title": "Safety and PK of HM10460A (HNK460) in Healthy Adult Japanese and Caucasian Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "HM10460A or placebo or Neulasta",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hanmi Pharmaceutical Company Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "20 Years to 45 Years"
      },
      "enrollment_count": 84,
      "start_date": "2009-11",
      "completion_date": "2011-04",
      "has_results": false,
      "last_update_posted_date": "2014-02-07",
      "last_synced_at": "2026-11-13T02:47:05.293Z",
      "location_count": 1,
      "location_summary": "California City, California",
      "locations": [
        {
          "city": "California City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01037543"
    },
    {
      "nct_id": "NCT01603147",
      "title": "Safety Study of Ch-mAb7F9 for Methamphetamine Abuse",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Methamphetamine Abuse"
      ],
      "interventions": [
        {
          "name": "normal saline",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ch-mAb7f9",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "InterveXion Therapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 42,
      "start_date": "2012-04",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2014-05-13",
      "last_synced_at": "2026-11-13T02:47:05.293Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01603147"
    },
    {
      "nct_id": "NCT01793649",
      "title": "A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cystic Fibrosis",
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "GS-5737",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 7,
      "start_date": "2012-10",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2014-03-20",
      "last_synced_at": "2026-11-13T02:47:05.293Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01793649"
    },
    {
      "nct_id": "NCT06511973",
      "title": "A Study to Learn About Whether BAYH006689 Causes Skin Irritation When Applied as a Topical Gel in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pain",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Naproxen (BAYH006689)",
          "type": "DRUG"
        },
        {
          "name": "Placebo Gel",
          "type": "DRUG"
        },
        {
          "name": "A solution of 0.9% Saline",
          "type": "DRUG"
        },
        {
          "name": "A solution of 0.2% SLS",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2024-07-23",
      "completion_date": "2024-08-20",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-11-13T02:47:05.293Z",
      "location_count": 1,
      "location_summary": "Fair Lawn, New Jersey",
      "locations": [
        {
          "city": "Fair Lawn",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06511973"
    },
    {
      "nct_id": "NCT04909723",
      "title": "Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Healthy Volunteers",
        "Enteric Hyperoxaluria"
      ],
      "interventions": [
        {
          "name": "NOV-001",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "NB1000S",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NB2000P",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Novome Biotechnologies Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 153,
      "start_date": "2021-06-02",
      "completion_date": "2023-04-06",
      "has_results": false,
      "last_update_posted_date": "2023-05-17",
      "last_synced_at": "2026-11-13T02:47:05.293Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Daytona Beach, Florida + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04909723"
    },
    {
      "nct_id": "NCT03402373",
      "title": "Evaluation of the Nutritional Supplement Lycoderm on Its Impact on Skin Parameters",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Skin Care"
      ],
      "interventions": [
        {
          "name": "Lycoderm",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "LycoRed Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "55 Years",
        "sex": "FEMALE",
        "summary": "35 Years to 55 Years · Female only"
      },
      "enrollment_count": 60,
      "start_date": "2017-11-17",
      "completion_date": "2019-05-30",
      "has_results": false,
      "last_update_posted_date": "2019-07-02",
      "last_synced_at": "2026-11-13T02:47:05.293Z",
      "location_count": 1,
      "location_summary": "Port Chester, New York",
      "locations": [
        {
          "city": "Port Chester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03402373"
    },
    {
      "nct_id": "NCT02257151",
      "title": "Study to Evaluate the Safety, Pharmacokinetics and Target Engagement of BMS-986142 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Adult"
      ],
      "interventions": [
        {
          "name": "BMS-986142",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 118,
      "start_date": "2014-09",
      "completion_date": "2015-08",
      "has_results": false,
      "last_update_posted_date": "2015-09-24",
      "last_synced_at": "2026-11-13T02:47:05.293Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02257151"
    },
    {
      "nct_id": "NCT02508753",
      "title": "Safety Study Designed to Study the Effects of Two Different Doses of CXA-101/Tazobactam, a Low Dose and a High Dose, on the QT/QTc Intervals in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "CXA-101/tazobactam",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 52,
      "start_date": "2010-06",
      "completion_date": "2010-07",
      "has_results": false,
      "last_update_posted_date": "2017-01-26",
      "last_synced_at": "2026-11-13T02:47:05.293Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02508753"
    }
  ]
}